NO328354B1 - Mutante rekombinante allergener, fremgangsmate for fremstilling, farmasoytisk sammensetning og anvendelse. - Google Patents
Mutante rekombinante allergener, fremgangsmate for fremstilling, farmasoytisk sammensetning og anvendelse. Download PDFInfo
- Publication number
- NO328354B1 NO328354B1 NO20004614A NO20004614A NO328354B1 NO 328354 B1 NO328354 B1 NO 328354B1 NO 20004614 A NO20004614 A NO 20004614A NO 20004614 A NO20004614 A NO 20004614A NO 328354 B1 NO328354 B1 NO 328354B1
- Authority
- NO
- Norway
- Prior art keywords
- allergen
- recombinant
- naturally occurring
- amino acid
- bet
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title claims description 211
- 238000000034 method Methods 0.000 title claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 238000006467 substitution reaction Methods 0.000 claims description 39
- 239000002904 solvent Substances 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 206010020751 Hypersensitivity Diseases 0.000 claims description 21
- 102220570133 Histone PARylation factor 1_K32Q_mutation Human genes 0.000 claims description 20
- 229960005486 vaccine Drugs 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 14
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 13
- 239000013573 pollen allergen Substances 0.000 claims description 11
- 241000219427 Fagales Species 0.000 claims description 10
- 102220468330 Tektin-1_Y96A_mutation Human genes 0.000 claims description 10
- 241000256856 Vespidae Species 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 102220503212 Thioredoxin_K72A_mutation Human genes 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 241000257303 Hymenoptera Species 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 241001674044 Blattodea Species 0.000 claims description 4
- 241000238710 Dermatophagoides Species 0.000 claims description 4
- 101000750404 Phoneutria keyserlingi CRISP-1 Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 241000256837 Apidae Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241000220221 Rosales Species 0.000 claims description 3
- 102200115877 c.165G>T Human genes 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 102220054671 rs145551875 Human genes 0.000 claims description 3
- 102220122430 rs778792339 Human genes 0.000 claims description 3
- 102220009776 rs80358500 Human genes 0.000 claims description 3
- 241001536628 Poales Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000428 dust Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 239000002574 poison Substances 0.000 claims description 2
- 229960004784 allergens Drugs 0.000 description 50
- 210000002966 serum Anatomy 0.000 description 50
- 230000000172 allergic effect Effects 0.000 description 40
- 208000010668 atopic eczema Diseases 0.000 description 40
- 230000005764 inhibitory process Effects 0.000 description 34
- 239000013615 primer Substances 0.000 description 30
- 230000035772 mutation Effects 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 101710123661 Venom allergen 5 Proteins 0.000 description 16
- 235000018185 Betula X alpestris Nutrition 0.000 description 15
- 235000018212 Betula X uliginosa Nutrition 0.000 description 15
- 208000026935 allergic disease Diseases 0.000 description 15
- 230000028993 immune response Effects 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 238000002703 mutagenesis Methods 0.000 description 14
- 231100000350 mutagenesis Toxicity 0.000 description 14
- 230000007815 allergy Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000256838 Vespula Species 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 230000010807 negative regulation of binding Effects 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 8
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000235058 Komagataella pastoris Species 0.000 description 7
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000004472 Lysine Chemical group 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 101150096316 5 gene Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001142 circular dichroism spectrum Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000000760 immunoelectrophoresis Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 239000002578 wasp venom Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 235000001543 Corylus americana Nutrition 0.000 description 4
- 240000007582 Corylus avellana Species 0.000 description 4
- 235000007466 Corylus avellana Nutrition 0.000 description 4
- 241000238711 Pyroglyphidae Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 229940046533 house dust mites Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 239000002435 venom Substances 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- 210000001048 venom Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000219495 Betulaceae Species 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 102100036826 Aldehyde oxidase Human genes 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 206010003402 Arthropod sting Diseases 0.000 description 2
- 241000208837 Asterales Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000726768 Carpinus Species 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 241000723382 Corylus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000000731 Fagus sylvatica Species 0.000 description 2
- 235000010099 Fagus sylvatica Nutrition 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000209048 Poa Species 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000256834 Vespula vulgaris Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000002983 circular dichroism Methods 0.000 description 2
- 229940028617 conventional vaccine Drugs 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000006392 myotrophin Human genes 0.000 description 2
- 108010058605 myotrophin Proteins 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- QZCJOXAIQXPLNS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene 4-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCc1ccc(O)c(O)c1.FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F QZCJOXAIQXPLNS-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 239000010267 Allergoid Substances 0.000 description 1
- 241000219496 Alnus Species 0.000 description 1
- 241000219498 Alnus glutinosa Species 0.000 description 1
- 241000219497 Alnus incana Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000339490 Brachyachne Species 0.000 description 1
- 101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000726811 Carpinus betulus Species 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000037164 Collema parvum Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000209210 Dactylis Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- OAPNERBWQWUPTI-YUMQZZPRSA-N Lys-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O OAPNERBWQWUPTI-YUMQZZPRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000392928 Parachromis friedrichsthalii Species 0.000 description 1
- 101710096342 Pathogenesis-related protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000186704 Pinales Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241001124650 Polistes annularis Species 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 101710099833 Venom protein Proteins 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000003678 bronchial smooth muscle cell Anatomy 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 239000009342 ragweed pollen Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK36498 | 1998-03-16 | ||
| PCT/DK1999/000136 WO1999047680A1 (en) | 1998-03-16 | 1999-03-16 | Mutant recombinant allergens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20004614D0 NO20004614D0 (no) | 2000-09-15 |
| NO20004614L NO20004614L (no) | 2000-10-26 |
| NO328354B1 true NO328354B1 (no) | 2010-02-01 |
Family
ID=8092687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004614A NO328354B1 (no) | 1998-03-16 | 2000-09-15 | Mutante rekombinante allergener, fremgangsmate for fremstilling, farmasoytisk sammensetning og anvendelse. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040091500A1 (sl) |
| EP (1) | EP1062341B1 (sl) |
| JP (1) | JP2002506648A (sl) |
| KR (1) | KR20010041918A (sl) |
| CN (1) | CN1332029C (sl) |
| AT (1) | ATE408690T1 (sl) |
| AU (1) | AU749749B2 (sl) |
| CA (1) | CA2323687C (sl) |
| DE (1) | DE69939584D1 (sl) |
| DK (1) | DK1062341T3 (sl) |
| ES (1) | ES2313776T3 (sl) |
| HK (1) | HK1033591A1 (sl) |
| HU (1) | HUP0101464A3 (sl) |
| IL (2) | IL138339A0 (sl) |
| NO (1) | NO328354B1 (sl) |
| NZ (1) | NZ506665A (sl) |
| PL (1) | PL194804B1 (sl) |
| PT (1) | PT1062341E (sl) |
| WO (1) | WO1999047680A1 (sl) |
| ZA (1) | ZA200004819B (sl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE471377T1 (de) * | 2000-04-28 | 2010-07-15 | Novozymes As | Variante eines lipolytischen enzyms |
| IT1318690B1 (it) * | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti dell'allergene maggiore par j 2 di parietaria judaica. |
| IT1318692B1 (it) * | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche di phleum pratense. |
| DK1340085T3 (da) * | 2000-10-17 | 2008-12-01 | Besst Test Aps | Assay til direkte detektion af en biologisk celle i en legemsvæskepröve |
| NZ525820A (en) * | 2000-11-16 | 2005-01-28 | Alk Abello As | Mutant allergens |
| EP1219300B1 (en) * | 2000-12-28 | 2006-12-06 | BIOMAY Produktions- und Handels- Aktiengesellschaft | Treatment of allergies |
| JP2005508134A (ja) * | 2001-03-02 | 2005-03-31 | ザ ロックフェラー ユニヴァーシティ | 天然アレルゲンの免疫原性を保持する、アレルゲン性が低下した組み換えハイブリッドアレルゲン構築体 |
| WO2003031981A2 (en) * | 2001-10-05 | 2003-04-17 | Novozymes A/S | Kit for predicting binding of a specific antibody to a potential immunogen and method of screening |
| AU2003223934A1 (en) * | 2002-05-16 | 2003-12-02 | Alk Abello A/S | Recombinant bet. v. 1. allergen mutants, methods and process thereof |
| AU2003275941A1 (en) * | 2002-11-01 | 2004-05-25 | Alk-Abello A/S | Recombinant protein variants |
| MXPA05005528A (es) | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
| WO2004075875A1 (en) | 2003-02-28 | 2004-09-10 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| EP2272502A1 (en) | 2003-12-19 | 2011-01-12 | Alk-Abelló A/S | Cryogranules of a liquid composition of an allergen product |
| RU2008117396A (ru) | 2005-10-04 | 2009-11-10 | Альк-Абелло А/С (Dk) | Твердая вакцинная композиция |
| ITMI20052517A1 (it) * | 2005-12-29 | 2007-06-30 | Lofarma Spa | Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa |
| AU2007241557A1 (en) * | 2006-04-20 | 2007-11-01 | National University Of Singapore | Recombinant lactobacillus and use of the same |
| MX2009008620A (es) * | 2007-02-15 | 2009-10-22 | Mannkind Corp | Un metodo para mejorar la respuesta de celulas t. |
| WO2008116936A1 (en) | 2007-03-28 | 2008-10-02 | Alk-Abelló A/S | Use of an adjuvanted allergy vaccine formulation for parenteral administration |
| EP2028188A1 (en) * | 2007-08-21 | 2009-02-25 | Biomay AG | Hypoallergenic molecules |
| DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| ES2606550T3 (es) | 2009-06-19 | 2017-03-24 | Alk-Abelló S.A. | Nueva manera de administrar alérgeno en inmunoterapia específica con alérgenos |
| CN102584966A (zh) * | 2011-11-14 | 2012-07-18 | 广州医学院第二附属医院 | 一种重组花生过敏原与突变体及其制备方法和应用 |
| CN102690340A (zh) * | 2012-03-30 | 2012-09-26 | 广州医学院第二附属医院 | 一种重组巴西坚果过敏原与突变体及其制备方法和应用 |
| CN102617719A (zh) * | 2012-03-30 | 2012-08-01 | 广州医学院第二附属医院 | 一种重组大米过敏原与突变体及其制备方法和应用 |
| CN102603879A (zh) * | 2012-03-30 | 2012-07-25 | 广州医学院第二附属医院 | 一种重组大豆过敏原与突变体及其制备方法和应用 |
| CN102617715A (zh) * | 2012-03-30 | 2012-08-01 | 广州医学院第二附属医院 | 一种重组真菌主要过敏原与突变体及其制备方法和应用 |
| CN102675439A (zh) * | 2012-03-31 | 2012-09-19 | 广州医学院第二附属医院 | 一种重组黑麦草花粉过敏原与突变体的制备方法和应用 |
| EP2952200A1 (en) | 2014-06-04 | 2015-12-09 | Alk-Abelló A/S | Allergen for prophylactic treatment of allergy |
| CN111187606B (zh) * | 2020-02-25 | 2022-06-14 | 江苏海洋大学 | 一种用于海水基可循环清洁压裂液的表面活性剂及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804201A (en) * | 1996-03-11 | 1998-09-08 | The Rockefeller University | Immunomodulatory peptides of vespid antigen 5 |
| AU743647B2 (en) * | 1998-01-31 | 2002-01-31 | Mt. Sinai School Of Medicine Of New York University | Methods and reagents for decreasing allergic reactions |
| IT1318692B1 (it) * | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche di phleum pratense. |
-
1999
- 1999-03-16 AU AU27147/99A patent/AU749749B2/en not_active Ceased
- 1999-03-16 IL IL13833999A patent/IL138339A0/xx unknown
- 1999-03-16 DE DE69939584T patent/DE69939584D1/de not_active Expired - Lifetime
- 1999-03-16 ES ES99907345T patent/ES2313776T3/es not_active Expired - Lifetime
- 1999-03-16 CA CA002323687A patent/CA2323687C/en not_active Expired - Fee Related
- 1999-03-16 PT PT99907345T patent/PT1062341E/pt unknown
- 1999-03-16 AT AT99907345T patent/ATE408690T1/de active
- 1999-03-16 WO PCT/DK1999/000136 patent/WO1999047680A1/en active IP Right Grant
- 1999-03-16 CN CNB998040312A patent/CN1332029C/zh not_active Expired - Fee Related
- 1999-03-16 JP JP2000536863A patent/JP2002506648A/ja active Pending
- 1999-03-16 EP EP99907345A patent/EP1062341B1/en not_active Revoked
- 1999-03-16 PL PL343029A patent/PL194804B1/pl not_active IP Right Cessation
- 1999-03-16 DK DK99907345T patent/DK1062341T3/da active
- 1999-03-16 NZ NZ506665A patent/NZ506665A/en not_active IP Right Cessation
- 1999-03-16 HU HU0101464A patent/HUP0101464A3/hu unknown
- 1999-03-16 KR KR1020007010225A patent/KR20010041918A/ko not_active Application Discontinuation
-
2000
- 2000-09-07 IL IL138339A patent/IL138339A/en not_active IP Right Cessation
- 2000-09-12 ZA ZA200004819A patent/ZA200004819B/xx unknown
- 2000-09-15 NO NO20004614A patent/NO328354B1/no not_active IP Right Cessation
-
2001
- 2001-06-06 HK HK01103901A patent/HK1033591A1/xx not_active IP Right Cessation
-
2003
- 2003-11-20 US US10/719,553 patent/US20040091500A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2714799A (en) | 1999-10-11 |
| HUP0101464A2 (hu) | 2001-08-28 |
| ATE408690T1 (de) | 2008-10-15 |
| KR20010041918A (ko) | 2001-05-25 |
| NO20004614D0 (no) | 2000-09-15 |
| EP1062341B1 (en) | 2008-09-17 |
| DE69939584D1 (de) | 2008-10-30 |
| CA2323687C (en) | 2008-11-25 |
| JP2002506648A (ja) | 2002-03-05 |
| PL343029A1 (en) | 2001-07-30 |
| PL194804B1 (pl) | 2007-07-31 |
| CN1332029C (zh) | 2007-08-15 |
| CN1293710A (zh) | 2001-05-02 |
| NZ506665A (en) | 2003-08-29 |
| HK1033591A1 (en) | 2001-09-07 |
| PT1062341E (pt) | 2008-12-24 |
| IL138339A (en) | 2009-06-15 |
| WO1999047680A1 (en) | 1999-09-23 |
| HUP0101464A3 (en) | 2004-10-28 |
| US20040091500A1 (en) | 2004-05-13 |
| EP1062341A1 (en) | 2000-12-27 |
| AU749749B2 (en) | 2002-07-04 |
| NO20004614L (no) | 2000-10-26 |
| CA2323687A1 (en) | 1999-09-23 |
| DK1062341T3 (da) | 2008-11-03 |
| IL138339A0 (en) | 2001-10-31 |
| ZA200004819B (en) | 2001-05-30 |
| ES2313776T3 (es) | 2009-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO328354B1 (no) | Mutante rekombinante allergener, fremgangsmate for fremstilling, farmasoytisk sammensetning og anvendelse. | |
| CA2429172C (en) | Novel mutant allergens | |
| AU2002223505A1 (en) | Mutant allergens | |
| US20120283421A1 (en) | Methods and reagents for decreasing clinical reaction to allergy | |
| Westritschnig et al. | Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7 | |
| WO2003096869A2 (en) | Recombinant bet. v. 1. allergen mutants, methods and process thereof | |
| CA2513711C (en) | Process for the preparation of hypoallergenic mosaic antigens | |
| US20110052639A1 (en) | Allergen mutants | |
| US20030175312A1 (en) | Novel mutant allergens | |
| JP2005508134A (ja) | 天然アレルゲンの免疫原性を保持する、アレルゲン性が低下した組み換えハイブリッドアレルゲン構築体 | |
| RU2285042C2 (ru) | Новые мутантные аллергены | |
| CA2549573C (en) | Dna sequence, and recombinant preparation of group 4 major allergens from cereals | |
| JP2007536893A5 (sl) | ||
| ZA200303667B (en) | Novel mutant allergens. | |
| US20150140024A1 (en) | Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues | |
| Ruffilli et al. | Characterization of a Dominant Epitope of the Major Allergens of Parietaria | |
| AU2013204574A1 (en) | DNA-sequence and recombinant production of group 4 major allergens from cereals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |